Digoxin is a cardiac glycoside drug used as an anti-arrhythmic agent, and in the treatment of heart failure.
For a full list of brand names for this drug used in NZ, please see the relevant entry in the NZ Formulary
Digoxin-specific antibodiy fragments are an antidote that may be used to treat digoxin overdose. These fragments cross-react with the digoxin assay and will cause falsely elevated results. Serum digoxin levels cannot be used for monitoring purposes after the administration of these fragments.
Some physiological states, such as pregnancy, chronic kidney disease and chronic liver disease are associated with endogenous digoxin-like substances that cross-react with the digoxin assay and will cause falsely elevated results.
A trough sample should be collected (i.e. taken immediately before the next dose is due).
Drug levels should not be checked until steady state pharmacokinetics have been achieved (i.e. at least 4-5 half-lives after starting the drug/changing dose - the half-life of digoxin is approximately 36 hours, but may be significantly longer in those with renal impairment).
If overnight - Chilled (2 - 8 degrees Celsius)
The standard half-life of digoxin is 36 hours, with time to steady-state of 7 days.
Refer to the CDHB Therapeutic Drug Monitoring Profiles for advice on how to interpret digoxin levels.
|Atrial fibrillation||1-2 mmol/L|
|Heart failure||0.6-2 mmol/L|
Immunoinhibition assay on a Beckman Coulter AU5822 analyser.
$14.94 (Exclusive of GST)
"*" indicates required fields